Psilocybin Legalisation US Is Accelerating — What Changes in 2026

Psilocybin legalisation is no longer a distant dream — it is happening right now. In the first months of 2026, three major developments in the United States have shifted the legal landscape for magic mushrooms faster than ever before. A pharmaceutical company is preparing to file the first-ever psilocybin drug application with the FDA. The DEA has dramatically increased how much psilocybin can be legally produced. And more than a dozen U.S. states are actively writing psilocybin into law. Together, these events signal a turning point — not just for the U.S., but for the world.

Compass Pathways: The First Psilocybin Drug Heading to FDA Approval

The biggest news in psilocybin legalisation this year comes from Compass Pathways, a UK-based company developing a synthetic psilocybin compound called COMP360. In February 2026, Compass announced that its second Phase 3 clinical trial (called COMP006) successfully met its primary endpoint for treatment-resistant depression (TRD). As a result, the company now plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration by the end of 2026.

If approved, COMP360 would become the first classic psychedelic ever authorised for medical use in the United States. That is a historic milestone for psilocybin legalisation.

What the Trial Found

In the COMP006 trial, patients received two 25 mg doses of COMP360, three weeks apart. Compared to a 1 mg control dose, the treatment group showed a statistically significant 3.8-point reduction on the MADRS depression scale (p<0.001). Nearly 40% of participants experienced a "clinically meaningful reduction" in symptoms. Moreover, improvements were visible from the very next day and remained stable through week 6.

Durability data from the companion COMP005 trial were equally encouraging. Treatment effects lasted through at least 26 weeks after just one or two sessions. Among patients who responded and received a second dose, 40% achieved full remission. Chief Medical Officer Guy Goodwin noted that the FDA had only requested 12 weeks of durability data: "We're providing that in spades."

What This Means for Psilocybin Legalisation

Wall Street clearly believes psilocybin legalisation through the FDA pathway is coming — Compass shares spiked over 50% on the news. Analyst Ritu Baral of TD Cowen expressed "strong conviction" that the drug will be approved and achieve "robust market uptake." If it reaches the market, COMP360 would compete directly with J&J's Spravato (esketamine), which already generated $1.7 billion in sales in 2025 — a 57% increase year-over-year.

However, there is a catch. Psilocybin is still classified as a Schedule I substance in the United States, meaning the DEA considers it to have "no accepted medical use." Even with a successful NDA, analysts warn that the actual launch could be delayed until late 2027 because of rescheduling requirements. Nevertheless, an FDA approval would send a powerful signal to regulators around the world that psilocybin is legitimate medicine.

DEA Raises Psilocybin Production Quotas by 67%

While the FDA pathway moves forward, another U.S. federal agency is also shifting its position on psilocybin. In January 2026, the Drug Enforcement Administration (DEA) finalised its annual production quotas for controlled substances — and the numbers for psychedelics jumped dramatically.

This is significant for psilocybin legalisation because research can only happen if enough legal material exists. For years, the limited supply of legally produced psilocybin has been a bottleneck for clinical trials. By raising these quotas, the DEA is effectively clearing the path for more research — which in turn accelerates the case for broader legalisation.

The DEA stated it was increasing these quotas so that researchers can study psychedelics as a "potential treatment of conditions such as PTSD and depression." Notably, the final numbers exceeded the DEA's own initial proposal — public comments from researchers and institutions pushed the totals higher. As psychedelic researcher Dr. Matthew Johnson put it: "This isn't a green light for widespread commercialization, but it removes a bottleneck for evidence-building."

The psilocyn increase is especially noteworthy — a jump of 122%. Psilocyn (also spelled psilocin) is the active metabolite of psilocybin, meaning it is the molecule that actually works in the brain. More psilocyn production means more research into how the compound behaves, which feeds directly into the clinical evidence that drives psilocybin legalisation forward.

U.S. States Are Writing Psilocybin Legalisation into Law

Federal approval through the FDA may still take a year or two. In the meantime, individual U.S. states are not waiting. In early 2026, more than a dozen states have active bills related to psilocybin access, ranging from hospital-based pilot programs to full regulated-access systems. This state-level momentum is a critical part of the broader psilocybin legalisation movement.

States That Have Already Legalised Psilocybin Access

Before looking at what is new, it helps to know where psilocybin is already legal in the U.S. Three states currently allow some form of legal access:

New Psilocybin Legalisation Bills in 2026

The list of states pushing new psilocybin legislation in 2026 is long — and growing. Here are the most important ones:

Psilocybin Legalisation Beyond the United States

The U.S. may be generating the most headlines, but psilocybin legalisation is a global trend. Several countries have already moved ahead — and some are further along than you might think.

Czech Republic — Medical Psilocybin Since January 2026

On January 1, 2026, the Czech Republic became the first country in the European Union to legalise the medical use of psilocybin. Under a new criminal law amendment, certified psychiatrists and psychotherapists can now prescribe and administer synthetic psilocybin to patients with treatment-resistant depression and other severe mental health conditions. A single dose may not exceed 35 mg, and the treatment must follow clinical protocols set by the Czech Psychiatric Society. Self-medication, home use, and recreational possession remain strictly illegal.

Australia — Prescription Psilocybin Since 2023

Australia was actually the first country in the world to allow national psilocybin prescriptions. Since July 2023, authorised psychiatrists have been permitted to prescribe psilocybin for treatment-resistant depression under the Therapeutic Goods Administration's (TGA) Authorised Prescriber scheme. Through September 2025, 47 patients had received psilocybin under this program, with zero serious adverse events reported. The scheme currently covers only treatment-resistant depression, but a submission is underway to expand access to patients with end-of-life distress.

The Netherlands — Legal Truffles and a Growing Research Role

The Netherlands holds a unique position in the global psilocybin landscape. While magic mushrooms (fruiting bodies) have been illegal since 2008, psilocybin truffles — the underground sclerotia of the same fungi — remain legal for sale and personal use. This makes the Netherlands one of the only places in the world where you can legally purchase a ready-to-use psilocybin product over the counter. In addition, Dutch universities are playing a leading role in European psilocybin research. The University Medical Center Groningen (UMCG) is coordinating PsyPal, the first EU-funded multi-site psilocybin clinical trial, with a €6.5 million budget.

Other Countries Moving Forward

Beyond these frontrunners, psilocybin legalisation is progressing in various forms around the world:

The Big Picture: Where Psilocybin Legalisation Is Heading

When you step back and look at these developments together, a clear pattern emerges. First, clinical research builds the evidence base — as Compass Pathways' Phase 3 results have done. Then, federal agencies respond by removing barriers to further research — as the DEA's quota increase shows. Finally, legislators act — as dozens of U.S. states and multiple countries are doing right now.

This cycle is accelerating. Each positive trial result makes the next psilocybin legalisation bill easier to pass. Each new law normalises the conversation and encourages more research funding. The momentum is real, and it is global.

That said, significant obstacles remain. Psilocybin is still a Schedule I substance in the U.S. and remains prohibited under the UN's 1971 Convention on Psychotropic Substances. Even where legal access exists — as in Oregon — high costs and limited infrastructure have slowed adoption. The path to widespread psilocybin legalisation will not be instant, but the direction of travel is unmistakable.

For now, the legal landscape varies enormously depending on where you live. Some places already offer legal access to psilocybin products, while others are years away. Understanding your local laws is essential — and staying informed is the best way to be ready when the rules change.